Wednesday, June 10, 2026

pharma Β· Schizophrenia Β· Narcolepsy Type 1

Alkermes Pharma Ireland

Alkermes Pharma Ireland clinical programs β€” 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Dublin, USA HQ
27 Employees
EMA registrant Type
Company details
Status
Public
HQ
Dublin, USA
Employees
27
Programs
6
Drugs
3
Patents
25
Intelligence Β· Clinical Programs

Alkermes Pharma Ireland projects

3 ClinicalTrials.gov programs sponsored by Alkermes Pharma Ireland.

Alkermes Pharma Ireland has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ALKS 2680-301

    Alkermes Pharma Ireland

    Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial
  2. ALKS 9072

    Alkermes Pharma Ireland

    Schizophrenia

    phase 3 small molecule completed

    1 trial
  3. ALKS 9072, Low Dose

    Alkermes Pharma Ireland

    Schizophrenia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Alkermes Pharma Ireland have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.